89bio, Inc. (ETNB)

NASDAQ: ETNB · IEX Real-Time Price · USD
15.09
-0.59 (-3.76%)
At close: Sep 27, 2023, 4:00 PM
14.94
-0.15 (-0.99%)
After-hours: Sep 27, 2023, 7:30 PM EDT
-3.76%
Market Cap 1.14B
Revenue (ttm) n/a
Net Income (ttm) -118.64M
Shares Out 75.48M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,132,720
Open 15.72
Previous Close 15.68
Day's Range 15.00 - 15.91
52-Week Range 5.24 - 22.93
Beta 0.72
Analysts Strong Buy
Price Target 38.75 (+156.79%)
Earnings Date Nov 9, 2023

About ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2019
Employees 45
Stock Exchange NASDAQ
Ticker Symbol ETNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ETNB stock is "Strong Buy." The 12-month stock price forecast is $38.75, which is an increase of 156.79% from the latest price.

Price Target
$38.75
(156.79% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the four...

6 days ago - GlobeNewsWire

89bio to Participate in the 2023 Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

7 days ago - GlobeNewsWire

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

22 days ago - GlobeNewsWire

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress –

7 weeks ago - GlobeNewsWire

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...

2 months ago - GlobeNewsWire

Weight-loss drugs in development aim to replace injections with pills

Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in ...

Other symbols: AKROLLYMDGLNVOPFEVRTX
3 months ago - Market Watch

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile –

3 months ago - GlobeNewsWire

Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints –

3 months ago - GlobeNewsWire

89bio shares rise as analysts see improved outlook for NASH treatments

Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the stock with an outperform rating. The company is f...

3 months ago - Market Watch

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...

4 months ago - GlobeNewsWire

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

4 months ago - GlobeNewsWire

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

4 months ago - GlobeNewsWire

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Positive topline results from ENLIVEN Phase 2b trial of pegozafermin in NASH demonstrated high statistical significance on both primary histology endpoints supporting advancement to Phase 3; discuss...

5 months ago - GlobeNewsWire

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

5 months ago - GlobeNewsWire

89bio's public stock offering upsized by 38%, priced at a 4% discount

89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The ...

6 months ago - Market Watch

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

6 months ago - GlobeNewsWire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

6 months ago - GlobeNewsWire

89bio's stock rallies 48% on new NASH data

Shares of 89bio Inc. ETNB, -7.06% soared about 48% in premarket trading on Wednesday after the company said its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution co...

6 months ago - Market Watch

89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0...

6 months ago - GlobeNewsWire

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

7 months ago - GlobeNewsWire

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying thera...

7 months ago - GlobeNewsWire

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

7 months ago - GlobeNewsWire

89bio to Participate in the SVB Securities Global Biopharma Conference

SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

8 months ago - GlobeNewsWire

89bio Provides Business Update and Outlook for 2023

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

9 months ago - GlobeNewsWire

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury...

10 months ago - GlobeNewsWire